Table 1. The effect of rapamycin on maximum lifespan.
Comparison | Sites | Age at 90th Percentile for Controls (UL*) | Age at 90th Percentile for Rapa | Percent Increase |
---|---|---|---|---|
Females, Rapa vs Control | All sites | 1094 (1136) | 1245 | 14% |
Females, Rapa vs Control | TJL | 1100 (1165) | 1282 | 17% |
Females, Rapa vs Control | UM | 1094 (1149) | 1250 | 14% |
Females, Rapa vs Control | UT | 1089 (1159) | 1179 | 8% |
Males, Rapa vs Control | All sites | 1078 (1111) | 1179 | 9% |
Males, Rapa vs Control | TJL | 1035 (1091) | 1142 | 10% |
Males, Rapa vs Control | UM | 1141 (1177) | 1188 | 4% |
Males, Rapa vs Control | UT | 1020 (1101) | 1179 | 16% |
Note: “UL” = upper limit of the 95% confidence interval for control mice. For example, top row, for females pooled across sites, the 95% confidence interval for controls goes up to 1136 days, and the estimate for 90th percentile survival for the rapamycin-treated mice is 1245 days. This gives good evidence that the 90th percentile survival for Rapa (1245) is substantially above that for Controls (1094).